|
Research Management and Support
|
RMS ES 2018
|
$340,640,887
|
$158,131
|
N/A
|
National Institutes of Health
|
|
Evaluation of an OCA2 enhancer variant as a modifier of the phenotype of BAP1-Tumor predisposition syndrome
|
1R21CA219884-01A1
|
$203,471
|
$50,868
|
ABDEL-RAHMAN, MOHAMED
|
OHIO STATE UNIVERSITY
|
|
Characterization of a novel RNA-guided endoRNAse and applications towards genome-wide screening for non-coding RNA roles in melanoma resistance
|
5F30CA210382-02
|
$49,524
|
$49,524
|
ABUDAYYEH, OMAR
|
HARVARD MEDICAL SCHOOL
|
|
Xeroderma Pigmentosum
|
ZIA CP010187 10777
|
$31,377
|
$6,275
|
Achatz, Maria Isabel
|
DCEG (NCI)
|
|
Plumbagin in Combination with Vemurafenib for BRAF-mutant Melanoma
|
5R03CA212798-02
|
$74,250
|
$74,250
|
AFAQ, FARRUKH
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer Center
|
3U10CA180791-04S1
|
$145,357
|
$7,268
|
AGHAJANIAN, CAROL
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer Center
|
5U10CA180791-05
|
$922,200
|
$46,110
|
AGHAJANIAN, CAROL
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Post-translational control of cancer cell stress response and metastasis
|
5R01CA202027-03
|
$459,505
|
$459,505
|
AIFANTIS, IANNIS
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
|
Naional Cancer Institute, Naitonal Clinical Trials Network U10 Lead Academic Site
|
5U10CA180790-05
|
$1,223,634
|
$48,945
|
ALBERTS, STEVEN
|
MAYO CLINIC ROCHESTER
|
|
Novel Strategies for Precision T-cell Therapies
|
3R01CA198095-03S1
|
$107,431
|
$53,716
|
ALMO, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Novel Strategies for Precision T-cell Therapies
|
5R01CA198095-03
|
$520,564
|
$260,282
|
ALMO, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Immunophenotyping by CyTOF and machine learning
|
ZIA BC 011807
|
$198,401
|
$79,360
|
Altan-Bonnet, Gregoire
|
CCR (NCI)
|
|
Consolidated Basic Cancer Research Program
|
3P30CA010815-49S1
|
$142,498
|
$31,350
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Consolidated Basic Cancer Research Program
|
3P30CA010815-49S2
|
$200,000
|
$44,000
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Consolidated Basic Cancer Research Program
|
5P30CA010815-49
|
$2,645,581
|
$582,028
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Molecular mechanisms of BRAF inhibitor induced UPR and autophagy
|
5R01CA198015-04
|
$366,000
|
$366,000
|
AMARAVADI, RAVI
|
UNIVERSITY OF PENNSYLVANIA
|
|
Biochemical Analysis of Multidrug Resistance-linked Transport Proteins
|
ZIA BC 010030
|
$753,084
|
$75,308
|
Ambudkar, Suresh
|
CCR (NCI)
|
|
The regulation of dendritic cell function by LMYC at steady state and during immune responses to cancer
|
1F31CA228240-01
|
$30,442
|
$7,611
|
ANDERSON, DAVID
|
WASHINGTON UNIVERSITY
|
|
Womens Health Initiative Cancer Survivor Cohort
|
3UM1CA173642-05S3
|
$175,562
|
$28,090
|
ANDERSON, GARNET
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Sensitization to CD47 Blockade to Enhance Anti-Tumor Immunity
|
5F30CA195973-04
|
$49,524
|
$49,524
|
ANDERSON, KATIE
|
UNIVERSITY OF MINNESOTA
|
|
Image guided immunotherapy and targeted radionuclide therapy of metastatic melanoma
|
5R01CA214018-02
|
$481,065
|
$481,065
|
ANDERSON, CAROLYN
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
FOXD3 up-regulation and ERBB3 signaling as an adaptive response to BRAF inhibitors in melanoma
|
2R01CA160495-06A1
|
$370,500
|
$370,500
|
APLIN, ANDREW
|
THOMAS JEFFERSON UNIVERSITY
|
|
Targeted therapies in mutant BRAF melanoma
|
5R01CA182635-05
|
$321,625
|
$321,625
|
APLIN, ANDREW
|
THOMAS JEFFERSON UNIVERSITY
|
|
Mutant BRAF-regulated transcription factors in melanoma progression
|
5R01CA196278-04
|
$356,850
|
$356,850
|
APLIN, ANDREW
|
THOMAS JEFFERSON UNIVERSITY
|
|
Hutchinson Center as Lead Academic Participating Site (U10)
|
5U10CA180828-05
|
$605,293
|
$30,265
|
APPELBAUM, FREDERICK
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Stanford Cancer Institute
|
3P30CA124435-11S1
|
$248,520
|
$2,485
|
ARTANDI, STEVEN
|
STANFORD UNIVERSITY
|
|
Stanford Cancer Institute
|
3P30CA124435-11S2
|
$171,518
|
$1,715
|
ARTANDI, STEVEN
|
STANFORD UNIVERSITY
|
|
Stanford Cancer Institute
|
5P30CA124435-11
|
$3,334,464
|
$33,345
|
ARTANDI, STEVEN
|
STANFORD UNIVERSITY
|
|
Cancer Center Support Grant - UT Southwestern Medical Center
|
3P30CA142543-09S1
|
$249,371
|
$7,481
|
ARTEAGA, CARLOS
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
Cancer Center Support Grant - UT Southwestern Medical Center
|
5P30CA142543-09
|
$2,480,000
|
$74,400
|
ARTEAGA, CARLOS
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
Cancer Center Support Grant
|
2P30CA082103-19
|
$7,954,381
|
$238,631
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-19S1
|
$84,000
|
$2,520
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-19S2
|
$206,488
|
$6,195
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-19S3
|
$257,838
|
$7,735
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
CD200R signaling in tumor growth, immunity and immunotherapy
|
1R01CA211014-01A1
|
$356,850
|
$356,850
|
BAI, XUE-FENG
|
OHIO STATE UNIVERSITY
|
|
UW Comprehensive CANCER CENTER SUPPORT
|
2P30CA014520-44
|
$4,590,130
|
$413,112
|
BAILEY, HOWARD
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
UW Comprehensive CANCER CENTER SUPPORT
|
3P30CA014520-44S1
|
$250,000
|
$22,500
|
BAILEY, HOWARD
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
UW Comprehensive CANCER CENTER SUPPORT
|
3P30CA014520-44S2
|
$136,232
|
$12,261
|
BAILEY, HOWARD
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
UW Comprehensive CANCER CENTER SUPPORT
|
3P30CA014520-44S3
|
$75,711
|
$6,814
|
BAILEY, HOWARD
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
UW Comprehensive CANCER CENTER SUPPORT
|
3P30CA014520-44S4
|
$31,772
|
$2,859
|
BAILEY, HOWARD
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
Structure, Function, and Inhibition of the RhoGEF Trio - a Target in Uveal Melanoma
|
1F31CA224804-01A1
|
$35,917
|
$35,917
|
BANDEKAR, SUMIT
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
Vesicular Stomatitis Virus (VSV) Replication in Malignant Cells
|
5R01CA194404-04
|
$334,911
|
$100,473
|
BARBER, GLEN
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
|
A-to-I microRNA Editing and Melanoma Metastasis
|
1R21CA219958-01A1
|
$208,800
|
$208,800
|
BARELI, MENASHE
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
Anatomic Pathology Residency Program
|
ZIE BC 011384
|
$1,537,925
|
$61,517
|
Barr, Frederic
|
CCR (NCI)
|
|
Identification of MSKs as critical integrators of chromatin and transcription factor activation in melanoma
|
5F32CA217068-02
|
$59,038
|
$59,038
|
BARROWS, DOUGLAS
|
ROCKEFELLER UNIVERSITY
|
|
Memory potential, molecular characterization, and translational applications of the novel ThEO/TcEO T cell phenotype
|
4K00CA212447-03
|
$71,280
|
$71,280
|
BARTKOWIAK, TODD
|
VANDERBILT UNIVERSITY
|
|
Molecular and immunologic evolution of melanomas from pre-neoplastic lesions
|
5R35CA220481-02
|
$951,000
|
$951,000
|
BASTIAN, BORIS
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Prospective study of farmers and their families (Agricultural health study)
|
ZIA CP010119 02020
|
$592,688
|
$29,634
|
Beane Freeman, Laura
|
DCEG (NCI)
|
|
Cancer Center Support Grant
|
3P30CA042014-29S1
|
$125,000
|
$6,250
|
BECKERLE, MARY
|
UNIVERSITY OF UTAH
|
|
Cancer Center Support Grant
|
3P30CA042014-29S2
|
$250,000
|
$12,500
|
BECKERLE, MARY
|
UNIVERSITY OF UTAH
|
Total relevant funding to Melanoma for this search: $158,437,087
|